Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bio-Bank Corp. is currently managing 1 pending office action. This action is located in the Biotechnology & Pharmaceuticals technology area, reflecting the company's focus on this specialized field. With 1 pending office action, the portfolio's current prosecution activity is very concentrated.
The prosecution of this matter is handled by 1 distinct examiner within 1 distinct art unit. This relationship between the examiner and the art unit indicates a singular administrative path for the company's current filing. For practitioners, this means that the entirety of the company's active patent work is subject to the review of a specific individual in a specific office.
FUBARA, BLESSING M is the busiest examiner for this portfolio, with 1 busiest examiner pending action. This 1 busiest examiner pending action constitutes the whole of the 1 pending office action total. Because there is 1 distinct examiner involved, the company's immediate patent outcomes are entirely dependent on the feedback from FUBARA, BLESSING M.
This concentration in 1 distinct art unit and under 1 distinct examiner simplifies the logistical aspects of the 1 pending office action. However, it also requires a highly targeted strategy that addresses the specific tendencies of FUBARA, BLESSING M. Practitioners should prepare for a focused interaction where the examiner's history in the Biotechnology & Pharmaceuticals area will be the primary factor in the pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 1 | 62.2% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705736 | PH-RESPONSIVE HYDROGEL BIOCARRIER AND APPLICATION | FUBARA, BLESSING M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705736 | PH-RESPONSIVE HYDROGEL BIOCARRIER AND APPLICATION | FUBARA, BLESSING M | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705736 | PH-RESPONSIVE HYDROGEL BIOCARRIER AND APPLICATION | FUBARA, BLESSING M | 1615 | §102§103§112 | Non-Final OA | — | Pending | Oct 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBio-Bank Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Blessing M Fubara has the most, with 1 of Bio-Bank Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
